SKYE Stock Risk & Deep Value Analysis

Skye Bioscience presents a highly speculative, high-risk/high-reward opportunity. The company delivered positive top-line Phase 2a data for SBI-100 (glaucoma) in November 2024, validating its novel cannabinoid-derived therapeutic approach. This clinical de-risking is a significant positive. However, this progress is heavily overshadowed by severe financial distress, evidenced by a 1-for-20 reverse stock split in March 2026 and an extremely low market cap of $20M. While the TAM remains substantial and the scientific premise is strengthened, the company faces an imminent and critical need for significant capital to fund Phase 3 trials. The market's skepticism, despite positive data, reflects high concerns over future dilution and the challenging path to commercialization, significantly increasing the financial risk compared to the previous assessment. Leadership demonstrated execution on clinical milestones, but the stock's performance indicates fundamental financial challenges.